S Kaye
Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer
Sandhu S, Assiotis I, Olmos D, Yap T, Fong P, Tunariu N, Koh D, Molife L, Kaye S, Lord C, Ashworth A, Fenwick K, Campbell J, Omlin A, Hylands L, Miranda S, Barber L, Riisnaes R, Reid A, Attard G, Chen L, Kozarewa I, Gevensleben H, de Bono J. Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. Ann Oncol 2013; 24:1416-8.
Mar 22, 2013Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer
Mar 22, 2013Ann Oncol 2013; 24:1416-8
Sandhu S K, Assiotis I, Olmos D, Yap T A, Fong P, Tunariu N, Koh D, Molife L R, Kaye S, Lord C J, Ashworth A, Fenwick K, Campbell J, Omlin Aurelius, Hylands L, Miranda S, Barber L J, Riisnaes R, Reid A H, Attard G, Chen L, Kozarewa I, Gevensleben H, de Bono J
Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial
Rothermundt C, Hubner R, Ahmad T, Gibbens I, Keyzor C, Habeshaw T, Kaye S, Gore M. Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial. British journal of cancer 2006; 94:74-8.
Jan 16, 2006Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial
Jan 16, 2006British journal of cancer 2006; 94:74-8
Rothermundt Christian, Hubner R, Ahmad T, Gibbens I, Keyzor C, Habeshaw T, Kaye S, Gore M